Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Business Overview: ImmuCell Corporation is a biotechnology firm focused on developing passive antibody products and diagnostic tests. Key products include First Defense (for calf disease prevention) and the Kamar Heatmount Detector. The company is actively pursuing Phase I/II clinical trials and seeking corporate partners to fund development.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1996 | Nine Months Ended Sep 30, 1996 | Balance Sheet (Sep 30, 1996) |
|---|---|---|---|
| Total Revenues | $1,011,310 | $3,281,430 | -- |
| Net Loss | $(106,580) | $(253,549) | -- |
| Cash and Equivalents | -- | -- | $824,194 |
| Working Capital | -- | -- | $1,249,351 |
| Total Debt (Current + Long Term) | -- | -- | $853,219 |
| Net Cash Used in Operations (9mo) | -- | $(345,739) | -- |
Gross Margin: Product sales gross margin percentage was maintained between 49% and 55%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 14% year-over-year for the nine-month period ($3.28M vs. $3.81M). This was driven by a 29% drop in grant income and a 12% decline in product sales.
- Product Sales Mix: Sales of core products (First Defense and Kamar Heatmount Detector) decreased 5% year-to-date, attributed to weakness in the beef market. Conversely, sales of diagnostic immunoreagents dropped significantly, falling from 14% of product sales in 1995 to just 6% in 1996.
- Increased Losses: Net loss for the nine-month period widened significantly to $253,549 compared to a $21,100 loss in the prior year, primarily due to sustained R&D expenses exceeding grant and collaborative revenue.
- Liquidity Reduction: Cash and cash equivalents decreased by approximately $726,000 (47%) from the prior year-end, resulting from operating losses and capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur further operating losses to aggressively develop new products. The strategy involves demonstrating efficacy in clinical trials to secure corporate partners for funding.
- Capital Resources: The company believes it has sufficient capital to meet working capital requirements for the next twelve months.
- Grant Funding: The company holds three NIAID SBIR grants totaling approximately $1.05M. As of September 30, 1996, approximately $128,000 remained available to fund future expenditures.
- Joint Ventures: In Q3 1996, the company invested in two joint ventures: AgriCell (lactoferrin production) and Clearwater Diagnostics (water testing for Cryptosporidium). Total investment in joint ventures was $228,797.
- Debt Obligations: The company secured a new $200,000 note payable in September 1996 at 10.0% interest to fund equipment and building improvements. Total debt principal payments due in 1997 are approximately $231,000.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $345,739 net cash used in operating activities over nine months and the $726,000 reduction in cash reserves.
- Grant Dependency: Assess the risk associated with the expiration of current NIAID grants (ending Oct/Dec 1996) and the reliance on future funding for R&D.
- Market Sensitivity: Confirm the correlation between beef market prices and sales of the company's primary revenue-generating products (First Defense).
- Debt Service: Review the ability to service $231,000 in principal debt payments due in 1997 alongside ongoing operating losses.
- Joint Venture Terms: Examine the profit-sharing structure of the AgriCell joint venture, where the partner receives 90% of proceeds until their initial investment is recouped.